Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Inclusion Criteria: * Be between 18 and 70 years of age * Have a documented diagnosis of congenital AATD * Have a post-bronchodilator Forced Expired Volume in 1 second (FEV1) of ≥30% and \<80% and FEV1/forced vital capacity (FVC) \<70% * If receiving alpha-1 PI augmentation therapy, be willing to discontinue the treatment for the duration of the study Exclusion Criteria: * Had a moderate or severe pulmonary exacerbation during the 4 weeks before the study * History of lung or liver transplant * Any lung surgery during the past 2 years * Confirmed liver cirrhosis * Elevated liver enzymes * Severe concurrent disease * Females who are pregnant or breast-feeding or unwilling to practice effective contraception during the study * Infection with hepatitis A, B, or C, human immunodeficiency or parvovirus B19 * Smoking during the past 6 months * Use of systemic steroids within 4 weeks of the study * Use of antibiotics for an exacerbation within 4 weeks of the study